Ricki Fram, MD
Cardiovascular Disease · Pine Bluff, ARNPI 1992994396
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 406 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations.
Across 406 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Novartis$1K
- Johnson & Johnson$492
- Actelion Pharmaceuticals US, Inc.$415
- Merck$358
- Pfizer$315
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,325100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 71 | $1,217 |
| Novartis | 89 | $1,072 |
| Johnson & Johnson | 35 | $492 |
| Actelion Pharmaceuticals US, Inc. | 20 | $415 |
| Merck | 20 | $358 |
| Pfizer | 22 | $315 |
| E.r. Squibb & Sons, L.L.C. | 15 | $234 |
| Regeneron Healthcare Solutions, Inc. | 14 | $196 |
| Boston Scientific | 6 | $167 |
| Alnylam Pharmaceuticals Inc. | 13 | $163 |
| Lexicon Pharmaceuticals, Inc. | 9 | $161 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $157 |
| Medtronic(2 entities) | 9 | $153 |
| Sanofi-aventis U.S. LLC | 11 | $150 |
| Philips North America LLC | 7 | $139 |
| Boehringer Ingelheim | 9 | $132 |
| GSK | 8 | $124 |
| Abbott | 4 | $106 |
| Novo Nordisk | 4 | $94 |
| Scpharmaceuticals Inc. | 4 | $93 |
| Esperion Therapeutics, Inc. | 6 | $87 |
| AstraZeneca | 5 | $70 |
| Irhythm Technologies, Inc. | 2 | $41 |
| Mallinckrodt Enterprises LLC | 2 | $40 |
| Coloplast | 1 | $32 |
| Baxter Healthcare | 1 | $26 |
| Cvrx, Inc. | 1 | $26 |
| Kestra Medical Technology Services, Inc. | 1 | $25 |
| Bridgebio Pharma, Inc. | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Cardiovascular Systems Inc. | 3 | $18 |
How this compares
$6,346 in reported general payments places this provider in the 65th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 232 | $163,688 |
| EntrestoSacubitril/Valsartan | 186 | $135,409 |
| Repatha SureclickEvolocumab | 74 | $93,167 |
| XareltoRivaroxaban | 59 | $40,427 |
| Praluent PenAlirocumab | 13 | $18,177 |
| BrilintaTicagrelor | 33 | $12,619 |
| FarxigaDapagliflozin Propanediol | 17 | $12,350 |
| MultaqDronedarone Hcl | 14 | $9,780 |
| JardianceEmpagliflozin | 15 | $9,252 |
| Ranolazine ErRanolazine | 89 | $4,709 |
| Metoprolol Succinate | 422 | $4,340 |
| Potassium Chloride | 276 | $2,715 |
| Atorvastatin Calcium | 333 | $2,110 |
| Prasugrel Hcl | 25 | $1,877 |
| Hydralazine Hcl | 200 | $1,851 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $315 | $163,688232 claims |
| NovartisEntresto | $1,072 | $135,409186 claims |
| Johnson & JohnsonXarelto | $492 | $40,42759 claims |
| AstraZenecaBrilinta, Farxiga | $70 | $24,96950 claims |
| Sanofi-aventis U.S. LLCMultaq | $150 | $9,78014 claims |
| Boehringer IngelheimJardiance | $132 | $9,25215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Pine Bluff
- Nicholas WillisPine Bluff$15K
- Sadeem MahmoodPine Bluff$11K
- Shabbir DharamseyPine Bluff$6K
- Ian CawichLittle Rock$294K
- Barry TedderJonesboro$130K
- Harvinder DodEl Dorado$126K
- William RollefsonLittle Rock$74K
- Andre PaixaoLittle Rock$73K
- Julio SchwarzFort Smith$70K
- Maximiliano ArroyoJonesboro$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.